Maravai LifeSciences (MRVI) Misses Q2 EPS by 6c

Maravai LifeSciences (NASDAQ: MRVI) reported Q2 EPS of ($0.05), $0.06 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $68.91 million versus the consensus estimate of $71.13 million.

For earnings history and earnings-related data on Maravai LifeSciences (MRVI) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Morgan Stanley sees little room left in steel rally, cuts Cleveland-Cliffs rating
• Alphabet slides over 6% as AI brain drain and SpaceX slump converge